|
Jun 7
|
Corporate cash levels are starting to fall
|
|
Jun 7
|
Patents and economies of scale support Pfizer's wide moat
|
|
Jun 6
|
Challenges pharma companies face in push into US manufacturing
|
|
Jun 5
|
Sector Update: Health Care Stocks Edge Higher Thursday Afternoon
|
|
Jun 5
|
Johnson & Johnson Has Strong Drug Pipeline to Treat Cancer, Other Diseases, RBC Says
|
|
Jun 4
|
JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer
|
|
Jun 4
|
J&J may take a softer tariff hit after US-China pause, CFO says
|
|
Jun 4
|
Johnson & Johnson MedTech introduces automated system for surgical efficiency
|
|
Jun 3
|
ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study
|
|
Jun 3
|
Johnson & Johnson's Darzalex Faspro Regimen Improves Progression-Free Survival in Two Phase 3 Myeloma Trials
|
|
Jun 3
|
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma
|
|
Jun 3
|
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
|
|
Jun 3
|
Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients
|
|
Jun 3
|
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
|
|
Jun 3
|
Johnson & Johnson Says Akeega Has Potential to Slow Castration-Sensitive Prostate Cancer Growth
|
|
Jun 3
|
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC
|
|
Jun 3
|
How leading oncology drugmakers set the stage for future advances
|
|
Jun 2
|
Johnson & Johnson (NYSE:JNJ) Unveils Promising Prostate Cancer Data With Pasritamig
|
|
May 29
|
HistoSonics’ histotripsy system receives early market access authorisation in UK
|
|
May 29
|
3 Elite High-Yield Dividend Stocks Down 8% to 27% That Have Hiked Their Payouts for More than 50 Years in a Row
|